Compare NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.06 (market cap $66.98B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.4 (market cap $2.27B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 29.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.5% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| NWG | SLS | |
|---|---|---|
Market Cap | $66.98B | $2.27B |
Volume | 5,259,060 | 4,179,659 |
Sector | Financials | Health |
52-Week High | $19.42 | $15.46 |
52-Week Low | $13.89 | $1.39 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $140.55B | $2.14B |
Dividend Yield | 5.5% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)
NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
